In recent years, great progress has been made in the research and development of inhibitors targeting fms-like tyrosine kinase 3 (FLT3) receptor kinase, and FLT3 inhibitors represented by Sorafenib and Midostaurin have been used for the treatment and research of AML [35]. Here, FLT3 is linked to acute myeloid leukemia.